MarketCapExport financials
BridgeBio Pharma (BBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
BridgeBio Pharma Income Statement 2025-2011 | BBIO
Brief overview of income trends at BridgeBio Pharma
The conclusions below are based on five years of reported results. BridgeBio Pharma reported revenue of $8.2 million in 2020 and $502 million by 2025. The cumulative result was +5986.5%, corresponding to roughly 127.4% per year. Sales grew at a rate typical of a strong expansion phase.
The operating result measured by EBITDA moved from −$473 million to −$518 million, or −9.5%. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −5734.3% to −103.2%. A wider margin confirms stronger operating efficiency.
Net income moved from −$505 million at the start to −$733 million at the end. The period ended with a larger loss than it began with.
The five-year change in capitalization reached +57.1%: from 8.3 billion dollars to 13.1 billion dollars. Market optimism is not supported by the direction of the results.
Summary assessment
The results present an uneven picture without one dominant signal. Key strengths include positive operating leverage and sales growth. The overall view is constrained by a narrow EBITDA buffer and lower net income. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement BridgeBio Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
13.1 B | 6.82 B | 5.45 B | 1.73 B | 1.13 B | 8.34 B | 3.67 B | - | - | - | - | - | - | - | - |
Shares |
192 M | 186 M | 163 M | 147 M | 144 M | 118 M | 105 M | - | - | - | - | - | - | - | - |
Historical Prices |
68.4 | 36.6 | 33.5 | 11.7 | 7.8 | 70.7 | 31.9 | - | - | - | - | - | - | - | - |
Net Income |
-733 M | -543 M | -653 M | -485 M | -586 M | -505 M | -261 M | -131 M | -30.6 M | - | - | - | - | - | - |
Revenue |
502 M | 222 M | 9.3 M | 77.6 M | 69.7 M | 8.25 M | 40.6 M | - | - | - | - | - | - | - | - |
Cost of Revenue |
21 M | 3.88 M | 2.45 M | 3.43 M | 3.11 M | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
481 M | 218 M | 6.86 M | 74.2 M | 66.6 M | - | 38.1 M | - | - | - | - | - | - | - | - |
Operating Income |
-523 M | -593 M | -607 M | -512 M | -577 M | -474 M | -266 M | -184 M | -43.9 M | - | - | - | - | - | - |
Interest Expense |
43.1 M | 12.3 M | 81.3 M | 80.4 M | 46.8 M | 36.7 M | 8.76 M | 2.55 M | 13 K | - | - | - | - | - | - |
EBITDA |
-518 M | -587 M | -601 M | -505 M | -571 M | -473 M | -279 M | -183 M | -43.8 M | - | - | - | - | - | - |
Operating Expenses |
1 B | 811 M | 614 M | 586 M | 643 M | 483 M | 304 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
531 M | 289 M | 151 M | 143 M | 192 M | 146 M | 94.4 M | 43.6 M | 13.3 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement BridgeBio Pharma
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
196 M | 196 M | 195 M | 682 K | 192 M | 191 M | 190 M | 1.13 M | 189 M | 188 M | 179 M | 3.9 M | 163 M | 161 M | 153 M | 631 K | 148 M | 147 M | 146 M | 312 K | 147 M | 147 M | 139 M | 332 K | 118 M | 117 M | 118 M | 4.24 M | 117 M | 92.9 M | 92.3 M | 92.1 M | 61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-83 M | -152 M | -164 M | -193 M | -183 M | -182 M | -167 M | -265 M | -162 M | -73.5 M | -35.2 M | -168 M | -177 M | -158 M | -140 M | -138 M | -137 M | -9.86 M | -196 M | -147 M | -156 M | -96.3 M | -163 M | -120 M | -116 M | -121 M | -91.8 M | -73.5 M | -60 M | -74.3 M | -69.4 M | - | -42.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
353 M | 244 M | 195 M | 154 M | 121 M | 111 M | 117 M | 5.88 M | 2.73 M | 2.17 M | 211 M | 1.74 M | 4.09 M | 1.64 M | 1.83 M | 1.87 M | 338 K | 73.7 M | 1.69 M | 12.9 M | 2.34 M | 54 M | 462 K | 122 K | 8.13 M | - | - | 13.8 M | 26.7 M | -4.96 M | -4.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
20.4 M | 15 M | 9.94 M | 8.11 M | 6.56 M | 3.65 M | 2.64 M | 2.08 M | 598 K | 598 K | 598 K | 598 K | 598 K | 599 K | 651 K | 647 K | 739 K | 700 K | - | 1.17 M | 1.45 M | 109 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
333 M | 229 M | 185 M | 146 M | 114 M | 107 M | 114 M | 3.8 M | 2.13 M | 1.57 M | 211 M | 1.15 M | 3.49 M | 1.04 M | 1.18 M | 1.22 M | -401 K | 73 M | - | 11.7 M | 890 K | 53.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.6 M | -107 M | -106 M | -140 M | -145 M | -134 M | -104 M | -226 M | -192 M | -176 M | 343 K | -177 M | -158 M | -146 M | -126 M | -129 M | -129 M | -80.2 M | -174 M | -166 M | -149 M | -94 M | -168 M | -127 M | -120 M | -125 M | -102 M | -78.6 M | -54.5 M | -69.3 M | -63.8 M | - | -41.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
2.12 M | 5.59 M | 4.25 M | 11.8 M | 16.5 M | 6.55 M | 8.23 M | 1.62 M | 1.8 M | -632 K | 9.48 M | 21.8 M | -5.28 M | 1.48 M | -601 K | 4.56 M | 6.33 M | -10.8 M | -7.58 M | 28.3 M | -684 K | 2.46 M | 5.77 M | 2.98 M | 9 K | -1.83 M | 474 K | -158 K | -166 K | 1.94 M | 1.67 M | - | 1.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-10.9 M | -106 M | -105 M | -139 M | -144 M | -134 M | -104 M | -225 M | -191 M | -175 M | 943 K | -177 M | -157 M | -145 M | -126 M | -129 M | -129 M | -79.6 M | -173 M | -164 M | -149 M | -90 M | -167 M | -127 M | -121 M | -123 M | -102 M | -78.6 M | -54.5 M | -69.3 M | -63.8 M | - | -41.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
344 M | 336 M | 291 M | 286 M | 259 M | 241 M | 218 M | 230 M | 194 M | 177 M | 210 M | 179 M | 161 M | 147 M | 127 M | 130 M | 129 M | 153 M | 174 M | 177 M | 150 M | 148 M | 168 M | 128 M | 128 M | 125 M | 102 M | 92.5 M | 81.3 M | 69.3 M | 63.8 M | - | 41.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
201 M | 186 M | 164 M | 158 M | 138 M | 129 M | 106 M | 94.8 M | 68.8 M | 59.5 M | 65.8 M | 47.6 M | 35.8 M | 36.1 M | 31.1 M | 31.9 M | 31.2 M | 36.4 M | 43.7 M | 54.7 M | 46.1 M | 46 M | 45.4 M | 37.4 M | 36 M | 38 M | 34.3 M | - | 23.5 M | 17 M | 18.9 M | - | 10.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company BridgeBio Pharma (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
Schweiz
Canada
Danmark
Britain
France
Irlanda
Germany
China